You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
REsilience & Stability In DENse Terrains (RESIDENT)
SBC: BOSTON FUSION CORP Topic: ST17C003Boston Fusion Corp. and Arizona State University will research and develop REsilience & Stability in DENse Terrains (RESIDENT), a multi-modal, multi-model, multi-scale framework for assessing indicators of stability and resilience in dense urban environments. Our team consists of subject matter experts in the Social and Computer Sciences providing the bedrock on which to build accurate mathematica ...
STTR Phase II 2020 Department of DefenseDefense Advanced Research Projects Agency -
Inhibitors of T3SS translocon assembly to combat multi-drug resistant P. aeruginosa
SBC: MICROBIOTIX, INC. Topic: NIAIDAbstract Pseudomonas aeruginosa (PA) is the bacterium most frequently isolated from the respiratory tract of ICU pa- tients in the US and is a major cause of pneumonia in intubated patients. Furthermore, infection with PA gener- ally has a poor prognosis, with an estimated 40-69% of PA ventilator-associated pneumonia (VAP) cases re- sulting in mortality, and more than 30% of survivors suffer recur ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Personalized anesthetic brain monitoring:Developing novel systems, sensors, and algorithms for aging, dementia, and Alzheimers disease patients
SBC: PASCALL Systems, Incorporated Topic: RPROJECT SUMMARY In the United States, nearly 100,000 patients receive general anesthesia and sedation daily to safely undergo surgical and non-surgical procedures. A high proportion of these patients are older than 65 years of age. These older patients are at higher risk of post-operative delirium and cognitive dysfunction. Many of these older patients have dementia, including mild cognitive impai ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
A new generation, enhanced, corneal-birefringence-independent retinalscanning device for pediatric vision disorders using polarization modulation
SBC: REBISCAN, Inc. Topic: NProject Summary/Abstract !Amblyopia is vision loss caused by neglect of a structurally normal eye due to strabismus, asymmetric refraction (anisometropia), or deprivation. It is irreversible if not treated by age 7, but half of all patients in the U.S. are undetected and untreated until after it is too late, making it the leading cause of preventable vision loss. Rebion (Rebiscan, Inc) has develop ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Drug target identification using CRISPRi/a screening
SBC: BIOIO, LLC Topic: 400ABSTRACT As phenotypic screening makes a comeback in drug discovery, its major issue is drug target identification. There aren’t good generalizable approaches to do target identification for compounds of interest. Identifying how a new drug works at the molecular level is critical for improving it, which is often needed to give it the best chance of ultimately being both safe and effective in pa ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Multi-Modal Venus Clot Removal Device
SBC: Caeli Vascular LLC Topic: NHLBIABSTRACTThis Phase I STTR application from Caeli Vascular, LLC entails a 12-month period focused on the development of a novel endovascular venous thrombectomy device. The PI is a vascular surgeon with biomedical research and entrepreneurship experience, and is supported by a team of highly qualified investigators, including a vascular biologist, neurosurgeon, veterinarian, biomedical engineer, me ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Treatment of diabetic retinopathy with TrkB agonist antibodies
SBC: ZEBRA BIOLOGICS INC Topic: NEIProject Summary/AbstractDiabetic retinopathy (DR) is a major co-morbidity for patients with Type 1 and Type 2 diabetes. The incidence and severity of DR increase with duration of diabetes and approximately 30 percent will experience vision-threatening deficits. Work over the past decade has shown that the neural deficits observed in DR occur early in the natural history of the disease and likely p ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
The Assessment of Smart Phone Everyday Tasks (ASSET): A new IADL test for early AD
SBC: ADK Group, LLC Topic: NIAProject SummaryImpairment in instrumental activities of daily living (IADL) is a hallmark of Alzheimer’s disease (AD) dementia and a major source of patient and caregiver burden. Similarly to cognitive changes in AD, subtle difficulties in IADL may begin even before the stage of amnestic mild cognitive impairment (MCI). Recently, greater emphasis has been placed on preclinical AD, which consists ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Salmonella typhimurium-based Bacteriotherapy for Orphan Benign Tumors: Neurofibromatosis Type II (NF2)
SBC: Mulberry Biotherapeutics, Inc. Topic: 102Neurofibromatosis type 2 (NF2) is a rare genetic disorder that affects about 1 in 25,000 individuals globally. While usually benign, these tumors result in severe morbidity and mortality in affected individuals. Almost all NF2 patients lose their hearing, and many lose the ability to walk and even to see. NF2 patients’ average age at death is 36 years, many of whom die in adolescence or early ad ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Novel insulin-sensitizing NASH/diabetes drugs.
SBC: BIOIO, LLC Topic: 300Obesity is associated with an increased risk of a number of chronic and progressive diseases and obesity- related metabolic diseases constitute a significant public health burden. The increased likelihood of developing insulin resistance and diabetes is probably the most commonly recognized risk of being obese. In addition, obesity is also associated with accumulation of lipid in the liver parench ...
STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health